Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US75886F1075
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000C734W3
REGN
Regeneron Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Regeneron Pharmaceuticals Inc
ISIN
US75886F1075
TICKER
REGN
MIC
XNAS
REUTERS
REGN.OQ
BLOOMBERG
REGN US
Do., 16.07.2026       Regeneron Pharmaceuticals
US75886F1075

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorde...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 25.06.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time t...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 22.06.2026       Regeneron Pharmaceuticals
US75886F1075

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       Regeneron Pharmaceuticals
US75886F1075

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 25.05.2026       Regeneron Pharmaceuticals
US75886F1075

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.If you are a long-term Regeneron Pharmaceuticals...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 25.05.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws.In March, the Senior Vice President of Investor Relations, Ryan Cr...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 22.05.2026       Regeneron Pharmaceuticals
US75886F1075

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Regeneron Pharmaceuticals
US75886F1075

Normalization of free light chains occurred by day 15 across all doses...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are encouraged to submit their information here. You may als...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Regeneron Pharmaceuticals
US75886F1075

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird ex Dividende/Zinsen gehandelt am 20.05.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its ex-dividend/interest day on 20.05.2026...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron executives pointed to optimistic outcomes for a study that was revealed to have failed to achieve its primary endpoint only two months later; shares dropped sharply when the results came in.NEW YORK, May 19, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw the stock decline more than 10% when the market open...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 19.05.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron's executives were optimistic about the potential for fianlimab + Libtayo; when the study failed to produce exepected results, the stock opened down more than 10%.NEW YORK, May 18, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) shareholders saw significant losses when the stock dropped sharply following the May 16, 2026 dis...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 18.05.2026       Regeneron Pharmaceuticals
US75886F1075

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird cum Dividende/Zinsen gehandelt am 19.05.2026 und ex Dividende/Zinsen am 20.05.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its pre-dividend/interest day on 19.05.2026 and its ex-dividend/interest day on 20.05.2026...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 18.05.2026       Regeneron Pharmaceuticals
US75886F1075

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws.In March, the Senior Vice President of Investor Relations, Ryan Cr...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Sa., 16.05.2026       Regeneron Pharmaceuticals
US75886F1075

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       Regeneron Pharmaceuticals
US75886F1075

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 08.05.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Regeneron Pharmaceuticals
US75886F1075

Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Regeneron Pharmaceuticals
US75886F1075

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Regeneron Pharmaceuticals
US75886F1075

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model ...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Regeneron Pharmaceuticals
US75886F1075

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische Gesundheitsdaten zu verknüpfenDurch diese Zusammenarbeit wird die weltweit führende, mit elektronischen Patientenakten verknüpfte Genom- und Proteom-Datenbank von Regeneron erweitert Die stet...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower A...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower A...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower A...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower A...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Regeneron Pharmaceuticals
US75886F1075

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Regeneron Pharmaceuticals
US75886F1075

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       Regeneron Pharmaceuticals
US75886F1075

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Srs. for Innovative Research...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       Regeneron Pharmaceuticals
US75886F1075

Key Takeaways:...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Regeneron Pharmaceuticals
US75886F1075

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Regeneron Pharmaceuticals
US75886F1075

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird ex Dividende/Zinsen gehandelt am 20.02.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its ex-dividend/interest day on 20.02.2026...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Regeneron Pharmaceuticals
US75886F1075

Das Instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY wird ex Dividende/Zinsen gehandelt am 20.02.2026 The instrument RGO US75886F1075 REGENERON PHARMAC.DL-,001 EQUITY has its ex-dividend/interest day on 20.02.2026...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Regeneron Pharmaceuticals
US75886F1075

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability ...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Regeneron Pharmaceuticals
US75886F1075

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       Regeneron Pharmaceuticals
US75886F1075

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 30.01.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update....
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 21.01.2026       Regeneron Pharmaceuticals
US75886F1075

The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 02.01.2026       Regeneron Pharmaceuticals
US75886F1075

TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM...
Zur Nachricht
Regeneron Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink